Human trials of Covaxin commence at Goa’s Redkar Hospital, to start in Odisha from Wednesday

ICMR and Bharat Biotech are jointly working on the clinical development of Covaxin, which has received approvals for phase-I and phase-II human trials

Asian News International July 21, 2020 07:58:23 IST
Human trials of Covaxin commence at Goa’s Redkar Hospital, to start in Odisha from Wednesday

Panaji: Goa Chief Minister Pramod Sawant has said that the human trials of coronavirus vaccine have begun at the state's Redkar Hospital and congratulated the team behind it.

Meanwhile, Preventive and Therapeutic Clinical Trial Unit was inaugurated at Bhubaneswar's Institute of Medical Sciences and SUM Hospital on Monday, ahead of the commencement of the human clinical trial of COVID-19 vaccine.

Covaxin is one of the first indigenous vaccines developed against COVID-19 and is derived from a strain of SARS-CoV-2 isolated by ICMR-National Institute of Virology (NIV), Pune. The Indian Council of Medical Research and Bharat Biotech are jointly working for the preclinical as well as clinical development of this vaccine. It has already received approval for phase-I and phase-II human trials by the Drug Controller General of India (DGCI).

Professor G Sahoo, Dean, IMS and SUM Hospital, Bhubaneswar speaking about the process told ANI that close to 30-40 candidates will be chosen for the first phase of the human trials which will commence from 22 July.

"Recruitment and screening of volunteers have already started. After screening, we will select healthy individuals between the age of 18-55 for the first phase of trials. We will start the first phase of human clinical trial of the COVID-19 vaccine from Wednesday, after that volunteer will be in contact with us for two to three months," Sahoo told ANI.

"We will monitor those candidates and they will be in constant touch with us. We will also call them here to test the antibody level in their blood after taking the vaccination if it found adequate, then we will go for the second and then for the third phase," he added.

The dean also said that till a vaccine is found and is made readily available, all the precautions for COVID-19 should be followed strictly by the people taking the rising number of the cases in the country in mind.

Further, Dr E Venkat Rao, principal investigator in the COVID-19 vaccine trials said, "We are committed to the maintenance of quality, ethics, patient safety and confidentiality of the highest level. We conduct clinical trials involving investigational drugs/molecules approved by the DCGI and the Central Drug Standardisation Control Organisation (CDSCO)."

Healthy volunteers who wish to participate in these clinical trials can contact the institution, to register online through their website- ptctu.soa.ac.in or contact +91 89172 11214 through WhatsApp, Dr Rao said.

Updated Date:

also read

Delta variant behind 86% of India's 'breakthrough' cases during COVID-19 second wave: ICMR study
India

Delta variant behind 86% of India's 'breakthrough' cases during COVID-19 second wave: ICMR study

The study indicated that majority of the clinical cases in the breakthrough were infected with the Delta variant in India. However, the death rate among vaccinated individuals was found to be low

COVID-19: Pakistan bans domestic air travel for unvaccinated as cases cross 1 million mark
World

COVID-19: Pakistan bans domestic air travel for unvaccinated as cases cross 1 million mark

The travel restriction, imposed by the National Command and Operation Centre (NCOC), will be applicable from 1 August on unvaccinated people of over 18 years of age

Over 3.09 crore unutilised vaccine doses available with states and private hospitals, says Centre
India

Over 3.09 crore unutilised vaccine doses available with states and private hospitals, says Centre

It said that more than 45.37 crore vaccine doses have been provided to states and UTs so far through all sources and a further 59,39,010 doses are in the pipeline